DIRS.INFO The most relevant business & tech news

☆ What it would take for humans to actually survive the harsh conditions on Dune's planet Arrakis
▼ + stars: | 2024-03-02 | by ( Jenny Mcgrath | ) www.businessinsider.com time to read: +9 min

Frank Herbert first described this harsh, fictional world of Arrakis in his 1965 novel "Dune," which was recently adapted into a film trilogy. The movie was shot in the deserts outside Abu Dhabi, but we wondered what it would actually take to survive on a real-life Arrakis. AdvertisementDune's planet Arrakis has enormous sandworms, a drug known as spice that helps with interstellar travel, and two moons. Planet Arrakis lacks oceans, lakes, or even tiny puddles on its surface. Surviving the temperature extremesIf the lack of water on Arrakis doesn't kill you, the heat certainly will if you're not prepared.

Persons: —, Frank Herbert, Seth Collings Hawkins, Amy J, it's, Alexander Farnsworth, Farnsworth, Herbert, Hawkins, Arrakis, Kreykes Organizations: Service, Business, Wake Forest University School of Medicine, University of Texas Medical Branch, Warner Bros, University of Bristol, Mexican - Locations: Abu Dhabi, Arrakis, Sonoran, Mexican, Mexican - U.S, Arizona , New Mexico, California

☆ After weight loss, Alzheimer's may be next frontier for drugs like Ozempic
▼ + stars: | 2023-05-08 | by ( Natalie Grover | ) www.reuters.com time to read: +6 min

LONDON, May 8 (Reuters) - Diabetes drugs that also promote weight loss such as Novo Nordisk’s (NOVOb.CO) Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer’s disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs. She said she has since been approached by pharmaceutical companies at an increasing pace, and is currently running an Alzheimer’s trial evaluating intranasal insulin in combination with another diabetes drug. Four companies with GLP-1 drugs, including two larger drugmakers, say they are watching for results of trials testing Novo's drug in Alzheimer's. Dementia affects more than 55 million people globally and the market for Alzheimer’s drugs is expected to grow to $9.4 billion by 2028 and for Parkinson’s to $6.6 billion, according to pharmaceutical data provider Citeline.

☆ FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease
▼ + stars: | 2023-03-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration's independent panel of advisors on Wednesday declined to endorse accelerated approval of Biogen's investigational ALS drug for a rare and aggressive form of the disease. The drug tofersen was developed to treat a rare genetic form of amyotrophic lateral sclerosis, or ALS. That number is even smaller in the U.S., with roughly 330 people affected by the SOD1 mutation. The median survival time from diagnosis with the rare form of ALS to death is 2.7 years, according to the company. The SOD1 mutation is associated with 20% of cases that occur within families.

☆ FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease
▼ + stars: | 2023-03-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration's independent panel of advisors on Wednesday voted against the effectiveness of Biogen's investigational ALS drug for a rare and aggressive form of the disease. The drug tofersen was developed to treat a rare genetic form of amyotrophic lateral sclerosis, or ALS. That number is even smaller in the U.S., with roughly 330 people affected by the SOD1 mutation. The median survival time from diagnosis with the rare form of ALS to death is 2.7 years, according to the company. The SOD1 mutation is associated with 20% of cases that occur within families.

Search resuls for: "Wake Forest University School of Medicine"

4 mentions found